Production (Stage)
Elicio Therapeutics, Inc.
ELTX
$5.66
$0.519.90%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.47% | -10.58% | -3.14% | 15.55% | 93.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.48% | -3.96% | 40.47% | 31.21% | 57.56% |
| Operating Income | -43.48% | 3.96% | -40.47% | -31.21% | -57.56% |
| Income Before Tax | -56.49% | -76.75% | 4.37% | -47.30% | -34.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.49% | -76.75% | 4.37% | -47.30% | -34.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.49% | -76.75% | 4.37% | -47.30% | -34.55% |
| EBIT | -43.48% | 3.96% | -40.47% | -31.21% | -57.56% |
| EBITDA | -43.80% | 3.87% | -41.33% | -32.02% | -58.88% |
| EPS Basic | 2.07% | -9.00% | 75.48% | 95.35% | 94.96% |
| Normalized Basic EPS | 3.22% | -10.08% | 77.29% | 95.35% | 94.90% |
| EPS Diluted | 2.07% | -9.00% | 75.48% | 95.35% | 94.96% |
| Normalized Diluted EPS | 3.22% | -10.08% | 77.29% | 95.35% | 94.90% |
| Average Basic Shares Outstanding | 59.79% | 62.15% | 290.05% | 3,069.98% | 2,568.76% |
| Average Diluted Shares Outstanding | 59.79% | 62.15% | 290.05% | 3,069.98% | 2,568.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |